课题基金 / 基金详情

IBR-COBRE Phase III

IBR-COBRE Phase III
IBR-COBRE III期
批准号:
10656277
负责人:
WILLIAM S WARD
金额:
$108.33万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-08-13 至 2025-05-31

项目摘要

项目成果

WILLIAM S WARD的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要--总体构成部分 2015年,美国约有7万名婴儿通过人工生殖受孕 技术(ART),它涉及两种技术之一:体外受精(IVF),其中精子 在体外使卵子受精,或将精子注入卵子的胞浆内单精子注射(ICSI) 使用微操作。艺术在世界范围内的迅速崛起,以及程序的持续发展 受雇于ART诊所,要求研究与时俱进,以确保ART的安全性并改进 生殖健康。从2000年开始只有三名教员,从2008年开始有Cobre的支持,IBR已经 在约翰·A·伯恩斯医学院(JABSOM)内,发展到四个系的14名全职教师, 夏威夷大学马诺阿分校(UHM)。在这14个项目中,科布雷第一阶段和第二阶段支持了10个项目,除了 其中两个已经获得了独立的NIH R系列资金。科布雷基金的直接结果是IBR已经 成为国际公认的生殖生物学卓越研究中心,并成为 世界上最好的小鼠配子操作中心(ICSI和IVF)。在第一阶段,IBR招募了 五名新教员,建立它作为生殖生物学研究所,并吸引了几个国家和 国际实习生。在第二阶段,第一阶段项目负责人成为导师和核心总监,而 维护他们自己的实验室。另外招聘了五名教员,带来了表观遗传学方面的专业知识, 生物信息学、基因编辑和器官开发,我们还与 产科、妇科和妇女健康(妇产科)。经过十年的支持,该中心是 现在竞争我们将在第三阶段寻求的几个赠款机会。第三阶段Cobre目标是 保持IBR Cobre作为世界级基础和翻译科学卓越中心的地位 生殖生物学。这将通过两个具体目标来实现。具体目标1:扩大和 使科布雷研究核心的专业知识多样化。扩大核心用户群并使其多样化,增强 精简核心运营,加强核心收入流,将导致 核心和加快科学发现的步伐,提高研究生产率,增加 争取外部资金的竞争力。具体目标2:制定和实施翻译试点项目 程序。我们将利用与司法部的牢固伙伴关系。Ob/Gyn将开发一种新的平移臂 为IBR做研究。在第三阶段Cobre结束时,我们设想每个核心都将完全或 通过充值账户、外部赠款、战略 投资和慈善事业,以及IBR将成功完成翻译的开发 研究机构通过一项新颖的试点项目方案实施。
英文摘要
PROJECT SUMMARY/ABSTRACT – Overall Component Approximately 70,000 babies born in the U.S. in 2015 were conceived by artificial reproductive technologies (ART), which involves one of two techniques: in vitro fertilization (IVF) in which the sperm fertilizes the egg in vitro, or intracytoplasmic sperm injection (ICSI) in which the sperm is injected into the egg using micromanipulation. The rapid rise in ART world wide, and continued developments of the procedures employed by ART clinics, requires that research keeps pace to ensure the safety of ART and to improve reproductive health. Starting with just three faculty in 2000, with COBRE support starting in 2008, the IBR has grown to 14 full-time faculty in four departments, within the John A. Burns School of Medicine (JABSOM), of the University of Hawaii at Manoa (UHM). Of these 14, the COBRE Phases I and II supported 10, and all but two have obtained independent NIH R-series funding. The direct result of COBRE funding is that the IBR has emerged as an internationally recognized center of research excellence for reproductive biology and one of the best centers in the world for mouse gamete manipulation (ICSI and IVF). During Phase I, the IBR recruited five new faculty, establishing it as a reproductive biology research institute and attracting several national and international trainees. During Phase II, the Phase I project leaders became mentors and core directors while maintaining their own labs. Five additional faculty were recruited, bringing expertise in epigenetics, bioinformatics, gene editing and organ development, and we also established a close partnership with the Department of Obstetrics, Gynecology and Women's Health (Ob/Gyn). After ten years of support, the center is now competitive for several grant opportunities that we will pursue in Phase III. Phase III COBRE objective is to sustain the IBR COBRE as a world-class basic and translational science center of excellence in reproductive biology. This will be accomplished through two Specific Aims. Specific Aim 1: Expand and diversify the expertise of the COBRE research cores. Growing and diversifying the core user base, enhancing and streamlining core operations, and strengthening the core revenue streams will result in the sustainability of the cores and accelerate the pace of scientific discovery, heighten research productivity and increase competitiveness for extramural funding. Specific Aim 2: Develop and implement a Translational Pilot Project Program. We will leverage a strong partnership with the Dept. of Ob/Gyn to develop a new translational arm of research for the IBR. At the end of the Phase III COBRE, we envision that each of the cores will be fully or largely self-sustained, through a coordinated plan of recharge accounts, extramural grants, strategic investments and philanthropy, and that a the IBR will have successfully completed development of translational research arm through a novel implementation of the pilot projects program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IBR-COBRE Phase III
  • 批准号:
    10726483
  • 项目类别:
  • 资助金额:
    $29.1万
  • 财政年份:
    2019
  • 负责人:
    WILLIAM S WARD
  • 依托单位:
Translational Pilot Project Program
  • 批准号:
    10225595
  • 项目类别:
  • 资助金额:
    $35.89万
  • 财政年份:
    2019
  • 负责人:
    WILLIAM S WARD
  • 依托单位:
Translational Pilot Project Program
  • 批准号:
    10656279
  • 项目类别:
  • 资助金额:
    $36.09万
  • 财政年份:
    2019
  • 负责人:
    WILLIAM S WARD
  • 依托单位:
Administrative and Mentoring Core
  • 批准号:
    10656286
  • 项目类别:
  • 资助金额:
    $31.96万
  • 财政年份:
    2019
  • 负责人:
    WILLIAM S WARD
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: